Scientists track mystery Drug's journey through 6 healthy volunteers
NCT ID NCT06626464
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study from Merck followed 6 healthy adults to see how the drug elpipodect (MK-8189) is absorbed, broken down, and eliminated. Participants took a single oral dose, and researchers measured the drug in blood, urine, and feces over time. The goal was purely to understand the drug's behavior in the body, not to test it for any specific disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Elpipodect (MK-8189)
What this could lead to
If successful, this study will help researchers understand how elpipodect moves through the body, which is a key step toward developing it as a treatment.
What could go wrong
This is a very early, small study in just 6 healthy people. It only looks at how the drug is processed, not whether it works for any disease. Results may not apply to patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Labcorp Clinical Research Unit Inc. (Site 0001)
Madison, Wisconsin, 53704, United States